FibroGen Inc (FGEN) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. lowered its stake in FibroGen Inc (NASDAQ:FGEN) by 73.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 15,382 shares of the biopharmaceutical company’s stock after selling 42,120 shares during the quarter. Russell Investments Group Ltd.’s holdings in FibroGen were worth $827,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 412 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in FibroGen by 1.7% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 474 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 696 shares during the last quarter. Tudor Investment Corp ET AL boosted its stake in FibroGen by 7.1% during the 2nd quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock worth $391,000 after purchasing an additional 799 shares during the last quarter. Finally, ProShare Advisors LLC boosted its stake in FibroGen by 3.6% during the 2nd quarter. ProShare Advisors LLC now owns 41,155 shares of the biopharmaceutical company’s stock worth $1,329,000 after purchasing an additional 1,416 shares during the last quarter. 57.23% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $44.66, for a total transaction of $1,725,483.76. Following the transaction, the chief executive officer now owns 3,022,934 shares in the company, valued at approximately $135,004,232.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider K Peony Yu sold 15,000 shares of FibroGen stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $60.00, for a total value of $900,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 287,446 shares of company stock worth $14,641,328. Insiders own 13.60% of the company’s stock.

FibroGen Inc (NASDAQ:FGEN) opened at $47.40 on Monday. FibroGen Inc has a fifty-two week low of $20.95 and a fifty-two week high of $60.15. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $3,896.16, a price-to-earnings ratio of -23.24 and a beta of 1.55.

Several brokerages have issued reports on FGEN. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. ValuEngine cut shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Mizuho reaffirmed a “hold” rating and set a $61.00 target price on shares of FibroGen in a research note on Thursday, November 9th. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 target price on shares of FibroGen in a research note on Thursday, September 14th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $75.00 target price on shares of FibroGen in a research note on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $65.67.

TRADEMARK VIOLATION NOTICE: This story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://transcriptdaily.com/2018/01/01/fibrogen-inc-fgen-shares-sold-by-russell-investments-group-ltd.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply